Mark Joinnides News Today

CAPE CANAVERAL, Fla., April 19, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (“Vaxxinity”, “we”, “us” or the “Company”) (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of

CAPE CANAVERAL, Fla., April 19, 2024 -- Vaxxinity, Inc. , a U.S. company pioneering the development of a new class of medicines, today announced its intention to voluntarily delist from the Nasdaq...

Presentation will address the Company’s clinical data in Parkinson’s diseaseCAPE CANAVERAL, Fla., March 28, 2024 -- Vaxxinity, Inc. , a U.S. company pioneering the development of a new class of...

Presentation will address the Company’s clinical data in Parkinson’s disease...

CAPE CANAVERAL, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of...

CAPE CANAVERAL, Fla., March 27, 2024 -- Vaxxinity, Inc. , a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the fourth...

CAPE CANAVERAL, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new clas...

Preclinical data published in the Journal of Lipid Research indicate VXX-401 is well-tolerated, with no safety signals observed, and robustly reduces LDL-C in cynomolgus monkeys. A Phase 1 trial of...

CAPE CANAVERAL, Fla., Jan. 03, 2024 -- Vaxxinity, Inc. , a U.S. company pioneering the development of a new class of medicines, today announced that Mei Mei Hu, Chief Executive Officer of...

CAPE CANAVERAL, Fla., Nov. 08, 2023 -- Vaxxinity, Inc. , a U.S. company pioneering the development of a new class of medicines, today reported financial results for the third quarter ended...